Strs Ohio reduced its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 8.9% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 20,400 shares of the biotechnology company’s stock after selling 2,000 shares during the period. Strs Ohio owned 0.11% of Enanta Pharmaceuticals worth $733,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Mason Street Advisors LLC boosted its stake in Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the last quarter. Louisiana State Employees Retirement System acquired a new stake in Enanta Pharmaceuticals during the second quarter worth $205,000. Aperio Group LLC acquired a new stake in Enanta Pharmaceuticals during the second quarter worth $206,000. Capstone Asset Management Co. acquired a new stake in Enanta Pharmaceuticals during the second quarter worth $212,000. Finally, Thrivent Financial For Lutherans boosted its stake in Enanta Pharmaceuticals by 5.1% in the first quarter. Thrivent Financial For Lutherans now owns 7,840 shares of the biotechnology company’s stock worth $241,000 after buying an additional 380 shares during the last quarter. 65.85% of the stock is owned by hedge funds and other institutional investors.

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ ENTA) opened at 37.91 on Tuesday. The firm’s market cap is $723.70 million. The firm’s 50-day moving average price is $37.82 and its 200-day moving average price is $32.79. Enanta Pharmaceuticals, Inc. has a 12 month low of $21.52 and a 12 month high of $41.20.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The company had revenue of $7.51 million during the quarter, compared to the consensus estimate of $8.08 million. During the same quarter in the prior year, the firm posted ($0.06) earnings per share. Enanta Pharmaceuticals’s revenue for the quarter was down 46.3% on a year-over-year basis. Analysts expect that Enanta Pharmaceuticals, Inc. will post $0.90 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/22/enanta-pharmaceuticals-inc-enta-stake-lowered-by-strs-ohio.html.

A number of research firms have recently weighed in on ENTA. J P Morgan Chase & Co reissued an “overweight” rating and issued a $38.00 price objective (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday, August 9th. Robert W. Baird lifted their price target on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Finally, JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a research report on Tuesday, July 11th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $36.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.